Cargando…

MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells

Chronic myeloid leukemia (CML) is a myeloproliferative disease. Imatinib (IM), the first line treatment for CML, is excessively expensive and induces various side effects in CML patients. Therefore, it is essential to investigate a new strategy for improving CML therapy. Our immunoblot data revealed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Tsung-Yao, Chen, Ku-Chung, Liu, Hsing-Jin Eugene, Liu, Ann-Jeng, Wang, Kun-Li, Shih, Chwen-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881950/ https://www.ncbi.nlm.nih.gov/pubmed/27228340 http://dx.doi.org/10.1371/journal.pone.0156260

Ejemplares similares

Correction: MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells
por: Lin, Tsung-Yao, et al.
Publicado: (2017)

SUMO-1 targets RanGAP1 to kinetochores and mitotic spindles
por: Joseph, Jomon, et al.
Publicado: (2002)

T-cell receptor (TCR) signaling promotes the assembly of RanBP2/RanGAP1-SUMO1/Ubc9 nuclear pore subcomplex via PKC-θ-mediated phosphorylation of RanGAP1
por: He, Yujiao, et al.
Publicado: (2021)

SUMO-1 Modification and Its Role in Targeting the Ran GTPase-activating Protein, RanGAP1, to the Nuclear Pore Complex
por: Matunis, Michael J., et al.
Publicado: (1998)

RanGAP1*SUMO1 is phosphorylated at the onset of mitosis and remains associated with RanBP2 upon NPC disassembly
por: Swaminathan, Sowmya, et al.
Publicado: (2004)

Novel plant SUN–KASH bridges are involved in RanGAP anchoring and nuclear shape determination
por: Zhou, Xiao, et al.
Publicado: (2012)

Molecular Characterization of the SUMO-1 Modification of RanGAP1 and Its Role in Nuclear Envelope Association
por: Mahajan, Rohit, et al.
Publicado: (1998)

The GTPase Activating Rap/RanGAP Domain-Like 1 Gene Is Associated with Chicken Reproductive Traits
por: Shen, Xu, et al.
Publicado: (2012)

The Cellular Distribution of RanGAP1 Is Regulated by CRM1-Mediated Nuclear Export in Mammalian Cells
por: Cha, Keith, et al.
Publicado: (2015)

SUMOylation mediates the disassembly of the Smad4 nuclear export complex via RanGAP1 in KELOIDS
por: Lin, Xiaohu, et al.
Publicado: (2023)

A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex
Publicado: (1996)

RanGAP‐mediated nucleocytoplasmic transport of Prospero regulates neural stem cell lifespan in Drosophila larval central brain
por: Wu, Di, et al.
Publicado: (2018)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

The Cyst Nematode SPRYSEC Protein RBP-1 Elicits Gpa2- and RanGAP2-Dependent Plant Cell Death
por: Sacco, Melanie Ann, et al.
Publicado: (2009)

The Ran GTPase-Activating Protein (RanGAP1) Is Critically Involved in Smooth Muscle Cell Differentiation, Proliferation and Migration following Vascular Injury: Implications for Neointima Formation and Restenosis
por: Vorpahl, Marc, et al.
Publicado: (2014)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

Determinants of Small Ubiquitin-like Modifier 1 (SUMO1) Protein Specificity, E3 Ligase, and SUMO-RanGAP1 Binding Activities of Nucleoporin RanBP2
por: Gareau, Jaclyn R., et al.
Publicado: (2012)

The RanBP2/RanGAP1*SUMO1/Ubc9 SUMO E3 ligase is a disassembly machine for Crm1-dependent nuclear export complexes
por: Ritterhoff, Tobias, et al.
Publicado: (2016)

The Proteolytic Activity of Separase in BCR-ABL-Positive Cells Is Increased by Imatinib
por: Haaß, Wiltrud, et al.
Publicado: (2012)

Identification of Drug Combinations Containing Imatinib for Treatment of BCR-ABL+ Leukemias
por: Kang, Yunyi, et al.
Publicado: (2014)

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
por: Wei, Liuya, et al.
Publicado: (2020)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
por: Sun, Xiaoyan, et al.
Publicado: (2016)

PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells
por: WU, NAN, et al.
Publicado: (2012)

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
por: Quentmeier, Hilmar, et al.
Publicado: (2011)

Inhibition of BCR/ABL Protein Expression by miR-203 Sensitizes for Imatinib Mesylate
por: Li, Yajuan, et al.
Publicado: (2013)

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
por: Low, Soon Khai, et al.
Publicado: (2022)

BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia
por: Cai, Zhimei, et al.
Publicado: (2020)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

Evolution and variability of Solanum RanGAP2, a cofactor in the incompatible interaction between the resistance protein GPA2 and the Globodera pallida effector Gp-RBP-1
por: Carpentier, Jean, et al.
Publicado: (2013)

Semi-random mutagenesis profile of BCR-ABL during imatinib resistance acquirement in K562 cells
por: Dong, Yan, et al.
Publicado: (2017)

Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation
por: Lan, Xiaoying, et al.
Publicado: (2017)

α-bisabolol Is an Effective Proapoptotic Agent against BCR-ABL(+) Cells in Synergism with Imatinib and Nilotinib
por: Bonifacio, Massimiliano, et al.
Publicado: (2012)

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
por: Okabe, Seiichi, et al.
Publicado: (2014)

Imatinib-resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprogramming
por: Zhao, Fangping, et al.
Publicado: (2010)

Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib
por: Blasiak, Janusz, et al.
Publicado: (2015)

Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia
por: Yusoff, Yuslina Mat, et al.
Publicado: (2018)

Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells
por: De Rosa, Viviana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a5kv2g2l6i7it2bb3iltrov1g9